Core Laboratories (CLB) Up 18.7% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Core Laboratories (CLB). Shares have added about 18.7% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Core Laboratories due for a pullback? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent drivers for Core Laboratories Inc. before we dive into how investors and analysts have reacted as of late.
Core Laboratories Q2 Earnings Beat Estimates, Decline Y/Y
Core Laboratories reported second-quarter 2026 adjusted earnings of 11 cents per share, which beat the Zacks Consensus Estimate of 8 cents, driven by outperformance of the Production Enhancement segment. However, the bottom line decreased from the year-ago quarter’s reported figure of 19 cents due to the underperformance of the Reservoir Description segment and increased costs and expenses.
This oilfield service provider reported second-quarter operating revenues of $124.6 million, missing the Zacks Consensus Estimate of $128 million and decreasing from the earlier-year quarter’s reported figure of $130.1 million. This can be attributed to military conflicts in the Middle East and the Russia-Ukraine region, which disrupted energy infrastructure, delaying projects, disrupting crude oil trade and reducing demand for the company's international laboratory services.
During the second quarter, CLB repurchased 214,712 shares of common stock for a total of $2.7 million. The company’s debt leverage ratio was at 1.30 and net debt decreased by $0.5 million.
Q2 Segmental Performance
Reservoir Description: Revenues in this segment decreased 8.7% from the year-ago quarter to $78.7 million. The top line also missed our model estimation of $82 million.
Operating income decreased from $12.2 million in the year-ago period to $3.7 million and missed our estimate of $6 million, caused by three primary factors: reduced client activity in the Middle East, lower global crude assay activity resulting from disruptions to hydrocarbon cargo shipments and increased military action and expanded European sanctions associated with the Russia-Ukraine conflict.
Production Enhancement: This segment’s revenues increased 4.5% to $45.9 million from $43.9 million in the prior-year quarter. The top line also beat our model estimate of $45.6 million.
Operating income increased from $3.1 million in the year-ago period to $5.2 million and beat our model estimate of $2 million. The outperformance in the Production Enhancement segment can be attributed to improvement in U.S. completion activity and increased product sales in both the U.S. and international markets.
Costs & Expenses
CLB reported total costs and expenses of $115.5 million in the second quarter, increasing by 0.5% from the year-ago quarter’s level of $114.9 million. Our estimation for the metric was $118.6 million.
Details of Financials & Dividends
As of June 30, 2026, the company had cash and cash equivalents of $22.7 million and long-term debt of $113.9 million. CLB’s debt-to-capitalization was about 29%.
Net cash provided by operating activities in the second quarter totaled $7.8 million, while capital expenditure amounted to $4.7 million. This led to a positive free cash flow of $3.1 million.
Core Laboratories’ board of directors approved a quarterly dividend of 1 cent per share to its common shareholders of record as of Aug. 10, 2026. The payout, which remains unchanged from the previous quarter, will be made on Aug. 31.
Management Remarks & Outlook for Q3
Ongoing conflicts in the Middle East and Russia-Ukraine prompted the IEA, EIA and OPEC to lower their 2026 global oil demand forecasts due to higher energy prices, supply disruptions and trade constraints. However, all three agencies expect demand growth to recover in 2027. Core Laboratories believes the long-term need for new production and enhanced recovery remains intact, supported by declining output from mature fields, energy security concerns and diversified hydrocarbon supply.
The company expects third-quarter revenues to rise sequentially, aided by improving activity in the South Atlantic Margin and Asia-Pacific, despite continued geopolitical disruptions affecting project execution and logistics. Modest improvement in U.S. land completions, growing adoption of its reservoir technologies and diagnostics, and expanding international offshore and exploration projects are expected to support long-term growth.
For the third quarter of 2026, CLB expects revenues to range from $128.5 million to $135.5 million. Operating income is anticipated to be between $10.5 million and $15 million, with earnings per share expected to be between 12 cents and 20 cents.
Revenues for the Reservoir Description segment are anticipated to be between $81 million and $84 million, with operating income ranging from $5.5 million to $7.9 million.
Revenues for the Production Enhancement segment are expected to be between $47.5 million and $51.5 million, with operating income predicted to be between $4.8 million and $6.9 million.
The company anticipates an effective tax rate of 25% for the third quarter. Its guidance for the third quarter of 2026 is based on estimates for underlying operations and excludes any gains or losses from foreign exchange.
Key Projects & Technology Advancements
During the second quarter of 2026, Core Laboratories expanded its technology-driven reservoir evaluation and completion capabilities through several projects across Asia-Pacific, Africa and the Middle East. In Australia, the company deployed its Advanced Digital Imaging System (ADIS) to analyze reservoir rock samples for an onshore gas project, integrating the results into its proprietary RAPID™ database to accelerate reservoir interpretation. Offshore Namibia, CLB applied advanced laboratory technologies to characterize geological and petrophysical properties, supporting more accurate reservoir models and reducing exploration risk.
The company also launched a reservoir characterization program for Murphy Oil's offshore Côte d’Ivoire discovery using its Dual Energy CT technology. In Asia-Pacific, Core Laboratories enabled a national oil company to establish in-house Tubing Conveyed Perforating capabilities through equipment supply and technical training. Additionally, regulatory approvals in the UAE for SpectraStim proppant tracing and SpectraScan spectral gamma ray logging broadened the company's reservoir optimization offerings, strengthening its position in a key Middle Eastern energy market.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions.
The consensus estimate has shifted -5.56% due to these changes.
VGM Scores
At this time, Core Laboratories has a poor Growth Score of F, however its Momentum Score is doing a bit better with a D. Charting a somewhat similar path, the stock was allocated a score of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Core Laboratories has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Core Laboratories belongs to the Zacks Oil and Gas - Field Services industry. Another stock from the same industry, Oceaneering International (OII), has gained 7.5% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.
Oceaneering International reported revenues of $768.18 million in the last reported quarter, representing a year-over-year change of +10%. EPS of $0.65 for the same period compares with $0.49 a year ago.
For the current quarter, Oceaneering International is expected to post earnings of $0.58 per share, indicating a change of +5.5% from the year-ago quarter. The Zacks Consensus Estimate has changed +9.4% over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #2 (Buy) for Oceaneering International. Also, the stock has a VGM Score of C.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Core Laboratories Inc. (CLB) : Free Stock Analysis Report
Oceaneering International, Inc. (OII) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
